Short description
Medifocus develops minimally-invasive treatment systems for the treatment of cancerous and benign tumors, as well as enlarged prostates.
Description
Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”). The Company owns two technology platforms with approximately 100 issued and pending US and international patents:
Based on these proprietary technology platforms, the Company has developed two advanced therapeutic products: the Adaptive Phased Array (APA)-1000 system for treatment of breast cancer and the Prolieve® system for the treatment of BPH. The APA-1000 uses precisely focused and controlled microwave energy to shrink breast cancer tumors without side-effects on the surrounding tissues to produce better treatment outcomes. The Company has received regulatory approvals to complete the APA 1000’s pivotal Phase-III clinical trials, the final step before marketing approval. The U.S. FDA-approved Prolieve® System is a medical device based on endo-thermotherapy that both heats the prostate and dilates the prostatic urethra. The Prolieve® System is a minimally invasive in-office treatment option for the symptoms of enlarged prostate in men. The Prolieve® System is a revenue generating product catering to the multi billion dollar BPH market. The Company is currently focusing on marketing Prolieve® for the treatment of BPH and accelerating the APA 1000 breast cancer system’s Phase III study.
Last funding
Nopepepe
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Columbia, Maryland, United States, North America
Founded on
January 1, 1996
Exited on
November 9, 2012
Went public on
November 9, 2012
Stock symbol
MDFZF
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$56378 - 90123
Sign in for full access